Time- and temperature-dependent Pentraxin 3 stability in serum and bronchoalveolar lavage fluid samples

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F25%3AA2603BVO" target="_blank" >RIV/61988987:17110/25:A2603BVO - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61388971:_____/25:00637560 RIV/61989592:15110/25:73633210 RIV/61989592:15310/25:73633210 RIV/00098892:_____/25:10159339 a 2 dalších

Výsledek na webu

<a href="https://academic.oup.com/mmy/article/doi/10.1093/mmy/myaf057/8176677" target="_blank" >https://academic.oup.com/mmy/article/doi/10.1093/mmy/myaf057/8176677</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/mmy/myaf057" target="_blank" >10.1093/mmy/myaf057</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Time- and temperature-dependent Pentraxin 3 stability in serum and bronchoalveolar lavage fluid samples

Popis výsledku v původním jazyce

Pentraxin 3 (Ptx3) is an acute-phase protein that specifically targets fungal galactosaminogalactan and has been proposed as a promising biomarker for invasive fungal infections. However, its stability in clinical samples over time has not yet been established. This study aimed to evaluate the stability of Ptx3 in serum and bronchoalveolar lavage fluid (BALF) samples during mid- and long-term storage. A total of 44 serum and 52 BALF samples were examined or re-examined for Ptx3 concentrations using enzyme immunoassay in pooled and individual sample formats. Samples were stored at −80°C, −20°C, and +37°C for periods ranging from 0 to 56 months. Statistical analyses included a paired two-sample Wilcoxon signed-rank test, analysis of variance, Bonferroni test, and linear regression analysis. Ptx3 remained highly stable in serum and BALF samples for up to 8 months at −20°C, with variations ranging from −1.8% to +2.8%. Long-term stability was observed at −80°C for 48 months, followed by a slow decline in Ptx3 levels. In contrast, storage at +37°C resulted in rapid degradation, with a 36.5%–60.7% increase or a 92.9%–97% decrease in Ptx3 levels in serum and BALF, respectively. These findings confirm that Ptx3 is a stable and reliable biomarker for invasive fungal infections when appropriate storage conditions are maintained.

Název v anglickém jazyce

Time- and temperature-dependent Pentraxin 3 stability in serum and bronchoalveolar lavage fluid samples

Popis výsledku anglicky

Pentraxin 3 (Ptx3) is an acute-phase protein that specifically targets fungal galactosaminogalactan and has been proposed as a promising biomarker for invasive fungal infections. However, its stability in clinical samples over time has not yet been established. This study aimed to evaluate the stability of Ptx3 in serum and bronchoalveolar lavage fluid (BALF) samples during mid- and long-term storage. A total of 44 serum and 52 BALF samples were examined or re-examined for Ptx3 concentrations using enzyme immunoassay in pooled and individual sample formats. Samples were stored at −80°C, −20°C, and +37°C for periods ranging from 0 to 56 months. Statistical analyses included a paired two-sample Wilcoxon signed-rank test, analysis of variance, Bonferroni test, and linear regression analysis. Ptx3 remained highly stable in serum and BALF samples for up to 8 months at −20°C, with variations ranging from −1.8% to +2.8%. Long-term stability was observed at −80°C for 48 months, followed by a slow decline in Ptx3 levels. In contrast, storage at +37°C resulted in rapid degradation, with a 36.5%–60.7% increase or a 92.9%–97% decrease in Ptx3 levels in serum and BALF, respectively. These findings confirm that Ptx3 is a stable and reliable biomarker for invasive fungal infections when appropriate storage conditions are maintained.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30109 - Pathology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Medical Mycology

ISSN

1369-3786

e-ISSN

1460-2709

Svazek periodika

—

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

—

Kód UT WoS článku

001525815700001

EID výsledku v databázi Scopus

2-s2.0-105010733754